menu
    • menu
    [{"orgOrder":0,"company":"Tivic Health","sponsor":"Statera Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"Entolimod","moa":"Toll-like receptor 5","graph1":"Hematology","graph2":"Phase III","graph3":"Tivic Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tivic Health \/ Tivic Health","highestDevelopmentStatusID":"10","companyTruncated":"Tivic Health \/ Tivic Health"},{"orgOrder":0,"company":"Tivic Health","sponsor":"Scorpius Holdings","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Agreement","leadProduct":"Entolimod","moa":"Toll-like receptor 5","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Tivic Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tivic Health \/ Tivic Health","highestDevelopmentStatusID":"10","companyTruncated":"Tivic Health \/ Tivic Health"},{"orgOrder":0,"company":"Tivic Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Entolimod","moa":"Toll-like receptor 5","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Tivic Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tivic Health \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Tivic Health \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Tivic Health

    Menu

    Tivic Health

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tivic Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Tivic Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Entolimod

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tivic Gets Two INDs For Entolimod In ARS And Advanced Cancers

                            Details : Entolimod is a novel TLR5 agonist that triggers NF-kB signaling, being investigated for the treatment of acute radiation syndrome and advanced cancers.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            August 20, 2025

                            Lead Product(s) : Entolimod

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tivic Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Tivic Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Entolimod

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase III

                            Recipient : Scorpius Holdings

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Tivic Signs GMP Validation Pact with Scorpius Ahead of FDA Submission

                            Details : Under the agreement, Scorpius will be the US manufacturer for Entolimod. It plans to utilize its technical expertise to validate the manufacturing process for Tivic’s lead candidate, Entolimod.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            May 14, 2025

                            Lead Product(s) : Entolimod

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase III

                            Recipient : Scorpius Holdings

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tivic Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Tivic Health

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Entolimod

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Recipient : Statera Biopharma

                            Deal Size : $1.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Tivic Expands TLR5 Entolimod License to Treat Neutropenia

                            Details : Under the licensing agreement, Tivic will obtains the rights of Entolimod TMC (entolimod). Iti s an being evaluated for treating for individuals with Neutropenia.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : $1.5 million

                            April 15, 2025

                            Lead Product(s) : Entolimod

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Recipient : Statera Biopharma

                            Deal Size : $1.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth